18,880
+0.43%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Huons Global Co
Its shares trade on KOSDAQ under the ticker 084110.KQ. It has been listed since 19 December 2006. In the fiscal year to 31 December 2025, it reported revenue of ₩847.45bn and net income of ₩28.84bn. At that date it held total assets of ₩1.56trn and shareholders' equity of ₩546.71bn.
Huons Global Co., Ltd. engages in the management of its subsidiaries and provision of botulinum toxin. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2006-12-19. Along with its subsidiaries, the Company operates its business through two segments: pharmaceutical segment and glass container segment. The pharmaceutical segment produces pharmaceutical products including parenteral injections such as lidocaines, merit C injections; tablets such as phentermines, diet pills and others; capsules such as Daisen and Fuxetine and other ethical and over-the-counter drugs. The glass container segment produces ampoules, vials, cartridges and caps for used of medicals, foods and cosmetics. The firm also manufactures medical devices such as kits, derma injectors and other injector.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 19 Dec 2006
- Website
- huonsglobal.com/web/home_.php ↗
Leadership
Pay as last reported
- Su Yeong SonPresident, Chief Executive Officer, Director, since 2022
- Gi An UhmManaging Director
- Hyeon Suk YooManaging Director, since 2012
- Yong Seung LeeAssistant Managing Director
- Ho Geun ChoiAssistant Managing Director
- Sang Man LeeAssistant Managing Director
- Yin Suk LeeInternal Auditor
- Bo Yeong YoonAssistant Managing Director, since 2009
- Wan Seop KimDirector, since 2017
- Jong Deok ChoiNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Huons Global Co Ltd operates in the Pharmaceuticals sector with a strong focus on botulinum toxin products.
- The company's pharmaceutical segment produces parenteral injections like lidocaines and merit C injections.
- Glass container segment supplies ampoules and vials for medical and cosmetic use.
Weaknesses
- The company's glass container segment is limited to medical, food, and cosmetic applications only.
- Pharmaceutical segment lacks diversity in product types beyond injections and tablets.
- No mention of international expansion or market diversification strategies.
Opportunities
- Growing demand for botulinum toxin products in the Health Care industry.
- Expanding pharmaceutical segment into new ethical and over-the-counter drugs.
- Increasing use of glass containers in medical and cosmetic industries.
Threats
- Competition from other pharmaceutical companies in the KR market.
- Regulatory changes affecting pharmaceutical product approvals.
- Dependence on the Korean market for revenue generation.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.